Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Cell Therapy

Cell Therapy

Cell Therapy: A promising field of regenerative medicine that involves the use of living cells to treat or prevent disease.
This approach aims to replace or repair damaged tissues and organs by introducing healthy cells, often derived from stem cells or other cell sources.
Cell Therapy encompasses a wide range of applications, including the treatment of degenerative conditions, autoimmune disorders, and cancer.
Researchers are continually exploring new cell types, delivery methods, and optimization strategies to enhance the efficacy and safety of Cell Therapy.
This dynamic field holds great potential to transform healthcare and improve patient outcomes.

Most cited protocols related to «Cell Therapy»

1
Standardizing Sickle Cell Disease Phenotypes
Cited 12 times
The Statistics and Data Management Center (SDMC) of the National Heart, Lung, and Blood Institute (NHLBI) Comprehensive Sickle Cell Centers (CSCC) Program was charged in 2003 with establishing a database of clinical, quality of life, and outcomes data to support development of multi-center research on SCD. A committee composed of representatives from 5 of the 10 participating clinical centers (C-Data Protocol Committee) assisted the SDMC in developing a protocol for this Collaborative Data Project (C-Data). The SDMC and C-Data Protocol Committee created a detailed case report form (CRF) designed to obtain comprehensive clinical, surgical, hospitalization, and laboratory data from medical record review to focus data collection on those features considered most important and most useful in identifying potential subjects for future trials. However, the lack of standard, universally applied definitions for clinical conditions or phenotypes used in the context of SCD initially threatened to make the collection of uniform data from existing medical records across sites impractical and likely impossible. Therefore, the Committee recommended initiation of a formal effort to establish standardized definitions for use in C-Data prospective data collection, CSCC future studies, and SCD research in general.
In parallel with this effort, an NIH-sponsored conference, “New Directions for Sickle Cell Therapy in the Genome Era”, listed as its highest priority the establishment of a SCD network that would include a comprehensive patient database and a biological sample repository to support examination of phenotypic diversity and serve as a resource for future research. As a result, the CSCC Center Directors, with support from the NHLBI, endorsed expansion of the C-Data Project to include the collection, testing, and storage of blood and DNA samples from participants. Based on this decision and the earlier recommendation of the C-Data Protocol Committee, the CSCC Steering Committee approved formation of an ad hoc work group to establish consensus definitions of the phenotypic manifestations of SCD.
Ballas S.K., Lieff S., Benjamin L.J., Dampier C.D., Heeney M.M., Hoppe C., Johnson C.S., Rogers Z.R., Smith-Whitley K., Wang W.C, & Telen M.J. (2010). Definitions of the Phenotypic Manifestations of Sickle Cell Disease. American journal of hematology, 85(1), 6-13.
Publication 2010
Biopharmaceuticals BLOOD Cells Cell Therapy Conferences Genome Heart Hospitalization Lung Operative Surgical Procedures Patients Phenotype Training Programs
2
Primary Culture of Human Neural Progenitors
Cited 11 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Brain Cell Therapy Fetal Tissue Fetus Genes Homo sapiens Nervousness
3
Isolation and Characterization of Human and Mouse BMSCs
Cited 11 times
BMSCs were defined by the International Society for Cellular Therapy. We obtained human bone marrow from the UAB Bone Cell Core Facility based on a protocol approved by the UAB Institutional Review Board. The plastic adherent human BMSCs were isolated by immunoselection using the mouse antibody to STRO-1 (dilution: 0.1 mg ml−1 and 10 μl of the diluted solution to 1–2.5 × 105 cells in a total reaction volume) and rat anti-mouse IgM-conjugated magnetic beads (Dynatech) according to the manufacturer’s directions (for in vitro migration assay). The adherent human BMSCs also were sorted by fluorescence-activated cell sorting (FACS) with the antibodies to CD45 (Bio-legend Inc) and CD146 (Abcam Inc) to harvest CD146+CD45− BMSCs. Mouse bone marrow cells were harvested and cultured. The adherent cells57 (link)–59 (link) were further sorted by FACS using the antibodies to CD29, Sca-1, CD45 and CD11b (Bio-legend Inc). The sorted cells were enriched by further culture and confirmed by flow cytometry. Colony forming unit-fibroblast (CFU-F)57 (link),59 (link) was analyzed by culturing 5 × 103 sorted cells to T-25 flask. The CFU-F colonies were further induced with osteogenic medium for seven days and analyzed with AP staining. The BMSCs cells were also cultured with or without osteogenic medium for 21 days for von Kossa or Alizarin Red staining.
Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., Zhao L., Nagy T.R., Peng X., Hu J., Feng X., Van Hul W., Wan M, & Cao X. (2009). TGF-β1-induced Migration of Bone Mesenchymal Stem Cells Couples Bone Resorption and Formation. Nature medicine, 15(7), 757-765.
Publication 2009
anti-IgM Antibodies Bone Marrow Cells CASP3 protein, human Cell Migration Assays Cells Cell Therapy Ethics Committees, Research Fibroblasts Flow Cytometry Homo sapiens Immunoglobulins ITGAM protein, human Mus Osteogenesis Technique, Dilution
4
Systemic Lupus Erythematosus Treatment Protocol
Cited 10 times
Enrolled patients were required, at a minimum, to meet the following criteria: 1) age ≥ 18 years; 2) a diagnosis of SLE according to the revised American College of Rheumatology criteria (22 (link)); 3) active disease (SELENA-SLEDAI score ≥ 6) at screening (18 (link)); and 4) seropositivity as defined by 2 positive ANA or anti-dsDNA test results (ANA titers ≥ 1:80 and/or anti-dsDNA antibodies ≥ 30 IU/mL), of which ≥ 1 test result had to be obtained during screening. The study entry criteria were identical to those in BLISS-52 (17 (link)). BLISS-76 enrolled patients from Europe and North/Central America (136 centers in 19 countries). A stable treatment regimen was required for ≥ 30 days before the first study dose; stable treatment could include prednisone (or equivalent) alone (7.5 to 40 mg/d) or combined (0 to 40 mg/d) with AM drugs, nonsteroidal anti-inflammatory drugs, and/or IS therapies. Exclusion criteria included serious intercurrent illness, severe active lupus nephritis, severe central nervous system manifestations, and pregnancy. Prior treatment with a B-cell–targeted therapy was exclusionary, as was any investigational biologic agent within 1 year of screening or investigational nonbiologic agent within 60 days. Additional medication exclusions included IV cyclophosphamide within 6 months, and a tumor necrosis factor inhibitor, anakinra, IV Ig, prednisone > 100 mg/d, or plasmapheresis within 3 months of screening, as well as immunization with a live vaccine within 1 month. Each site was required to obtain ethics committee/institutional review board approval of the final study protocol. Patients’ rights, safety, and well-being were protected based on the principles of the Declaration of Helsinki. Informed consent was obtained from each patient prior to study screening. The first patient was randomized in February 2007, and follow-up of the last patient was completed in March 2010.
Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzová D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., Stohl W., Ginzler E.M., Hough D.R., Zhong Z.J., Freimuth W, & van Vollenhoven R.F. (2011). A Phase 3, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits BLyS, in Patients With Systemic Lupus Erythematosus. Arthritis and rheumatism, 63(12), 3918-3930.
Publication 2011
Anakinra Anti-dsDNA antibody Anti-Inflammatory Agents, Non-Steroidal Biological Factors Cell Therapy Cyclophosphamide Diagnosis DNA, Double-Stranded Ethics Committees Ethics Committees, Research Immunization Institutional Ethics Committees Lupus Nephritis Patients Pharmaceutical Preparations Plasmapheresis Prednisone Pregnancy Safety Treatment Protocols Tumor Necrosis Factor Inhibitors Vaccines, Attenuated
5
Isolation and Characterization of Human and Mouse BMSCs
Cited 10 times
BMSCs were defined by the International Society for Cellular Therapy. We obtained human bone marrow from the UAB Bone Cell Core Facility based on a protocol approved by the UAB Institutional Review Board. The plastic adherent human BMSCs were isolated by immunoselection using the mouse antibody to STRO-1 (dilution: 0.1 mg ml−1 and 10 μl of the diluted solution to 1–2.5 × 105 cells in a total reaction volume) and rat anti-mouse IgM-conjugated magnetic beads (Dynatech) according to the manufacturer’s directions (for in vitro migration assay). The adherent human BMSCs also were sorted by fluorescence-activated cell sorting (FACS) with the antibodies to CD45 (Bio-legend Inc) and CD146 (Abcam Inc) to harvest CD146+CD45− BMSCs. Mouse bone marrow cells were harvested and cultured. The adherent cells57 (link)–59 (link) were further sorted by FACS using the antibodies to CD29, Sca-1, CD45 and CD11b (Bio-legend Inc). The sorted cells were enriched by further culture and confirmed by flow cytometry. Colony forming unit-fibroblast (CFU-F)57 (link),59 (link) was analyzed by culturing 5 × 103 sorted cells to T-25 flask. The CFU-F colonies were further induced with osteogenic medium for seven days and analyzed with AP staining. The BMSCs cells were also cultured with or without osteogenic medium for 21 days for von Kossa or Alizarin Red staining.
Tang Y., Wu X., Lei W., Pang L., Wan C., Shi Z., Zhao L., Nagy T.R., Peng X., Hu J., Feng X., Van Hul W., Wan M, & Cao X. (2009). TGF-β1-induced Migration of Bone Mesenchymal Stem Cells Couples Bone Resorption and Formation. Nature medicine, 15(7), 757-765.
Publication 2009
anti-IgM Antibodies Bone Marrow Cells CASP3 protein, human Cell Migration Assays Cells Cell Therapy Ethics Committees, Research Fibroblasts Flow Cytometry Homo sapiens Immunoglobulins ITGAM protein, human Mus Osteogenesis Technique, Dilution

Most recents protocols related to «Cell Therapy»

1
Pretargeted NK Cell Therapy for Murine Lymphoma
Not available on PMC !

Example 3

An in vivo experiment was performed using a murine lymphoma xenograft model. Pretargeted NK cell therapy as described herein was administered and associated with >50% reduction in tumor volume within 5 days of therapy. Treatment groups were compared with negative controls, including antibody treatment only and nontargeted NK cell therapy. Each treated animal received NK cells at 5×106 in PBS. Data from this experiment are shown in FIG. 11.

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

US11879010B2. Methods and compositions for pretargeted immunotherapy (2024-01-23). The Charlotte Mecklenburg Hospital Authority [US]. Inventors: Steven Park [US].
Full text: Click here
Patent 2024
Animals Cell Therapy Heterografts Immunoglobulins Lymphoma Mus Natural Killer Cells
2
Hematopoietic Advanced Cellular Therapies
Centers were requested to report patients receiving cellular therapies other than HCT. Hematopoietic advanced cellular therapies were defined as infusion of cells undergoing substantial manipulation after collection, either selection and/or expansion, or genetic modification and thus qualify as investigational or approved advanced therapy medicinal products (ATMPs) according to Regulation (EC) N° 1394/2007. In this context, “substantial” should be understood as referring to the definition included in the Regulation and subsequent regulatory documents and may not reflect the workload assumed by cell processing facilities working in conjunction with clinical programs. Depending on their nature and indications, hematopoietic cellular therapies may be designed to replace or to complement HCT. Administration of non-substantially manipulated hematopoietic cells, such as transplantation of CD34+ selected hematopoietic stem cells were counted as HCT and not as cellular therapy [18 (link)]. Similarly, un-manipulated lymphocyte infusions post-HCT were counted as donor lymphocyte infusions (DLI) and not as cellular therapy. Hematopoietic cellular therapies include immune effector cells as defined in FACT-JACIE standards for Hematopoietic Cellular Therapy: “A cell that has differentiated into a form capable of modulating or effecting a specific immune response.” This definition covers CAR-T cells and forms the basis for accreditation requirements in recent EBMT-JACIE recommendations [17 , 19 (link)].
Hematopoietic cellular therapies were categorized as chimeric antigen receptor T cells (CAR -T); in vitro selected/and or expanded T cells or cytokine activated, such as virus specific T cells; cytokine-induced killer cells (CIK); regulatory T cells (TREGS); genetically modified T cells other than CAR-T; natural killer cells (NK); dendritic cells; mesenchymal stromal cells; in vitro expanded CD34+ cells; and genetically modified CD34+ cells. This survey did not include cells from sources other than hematopoietic tissue. On the other hand, gene therapy protocols, such as those used to treat thalassemia or SCID were included, however numbers have remained low.
Passweg J.R., Baldomero H., Ciceri F., Corbacioglu S., de la Cámara R., Dolstra H., Glass B., Greco R., McLornan D.P., Neven B., de Latour R.P., Perić Z., Ruggeri A., Snowden J.A, & Sureda A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58(6), 647-658.
Full text: Click here
Publication 2023
Antigens Cells Cell Therapy Cytokine Cytokine-Induced Killer Cells Dendritic Cells Gene Editing Hematopoietic System Lymphocyte Mesenchymal Stromal Cells Natural Killer Cells Patients Pharmacotherapy Regulatory T-Lymphocytes Response, Immune SCID Mice T-Lymphocyte Thalassemia Therapy, Gene Tissue Donors Tissues Transplantation, Hematopoietic Stem Cell Virus
3
Global Hematopoietic Cell Transplant Rates
Transplant rates, defined as the total number of HCT per 10 million inhabitants were computed for each country, without adjusting for patients receiving their HCT in a foreign country. Cellular therapy rates were defined as the numbers of patients receiving a cellular therapy treatment per 10 million population. Population numbers for the European countries in 2021 were obtained from Eurostats: (https://ec.europa.eu/eurostat) and the World Bank database for the non-European countries: (https://databank.worldbank.org).
Passweg J.R., Baldomero H., Ciceri F., Corbacioglu S., de la Cámara R., Dolstra H., Glass B., Greco R., McLornan D.P., Neven B., de Latour R.P., Perić Z., Ruggeri A., Snowden J.A, & Sureda A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58(6), 647-658.
Full text: Click here
Publication 2023
Cell Therapy Europeans Grafts Patients
4
European Hematopoietic Cell Transplantation Report 2021
We invited participating centers to report their data for 2021 using the activity survey as shown in Table 1. Patients receiving their first transplant in the survey year are reported by disease, donor type and stem cell source. Additional information on the numbers of subsequent transplants performed due to relapse, rejection, or those that are part of a planned sequential protocol are reported in summative form. Information on the number of patients receiving un-manipulated donor lymphocyte infusions (DLIs), non-myeloablative or reduced intensity HCT, and the number of pediatric HCT were also collected.

Numbers of HCT in Europe 2021 by indication, donor type and stem cell source.

TRANSPLANT ACTIVITY 2021
No. of patients
AllogeneicAutologousTotal
FamilyUnrelatedAlloAutoTotal
HLA-idTwinHaplo ≥ 2MMOther familyBMBM + 
BMPBPCCordallBMPBPCBMPBPCCordBMPBPCCordonlyPBPCCord
Myeloid malignancies2242424333011593271130256921291226010,74522710,972
Acute myeloid leukemia1651700212171114243118235901061211071232127335
 1st complete remission10911581111959523011212070591182042661834449
 not 1st complete remission393731073338090328832702601775261801
AML therapy-related or myelodysplasia-related changes1716900251810402963720030108231085
Chronic myeloid leukemia893014540501321730403984402
 Chronic phase44100124050711620302003203
 Not chronic phase45201330000610110101981199
MDS or MD/MPN overlap444611160326021098138516090241392422
MPN7170002099020950040208112813
Lymphoid malignancies25113152419889064802472113531822,1110512722,12927,256
Acute lymphatic leukemia22678321137519329021011884605603144563200
 1st complete remission126565005127322101108251805301991532044
 not 1st complete remission100218218624618010036328030115331156
Chronic lymphocytic leukemia1510032801031020055018955244
Plasma cell disorders—MM3770243311021100612,931023312,93713,170
Plasma cell disorders—other012000400011900438036438474
Hodgkin lymphoma411500271001104156272288041022952705
Non-Hodgkin lymphoma1727701272061160275385563430111563487463
Solid tumors11101619000212031160405216351687
Neuroblastoma120051500021018525026543569
Soft tissue sarcoma/Ewing030012000020025508255263
Germinal tumors010100000000543102436438
Other solid tumors0500020000908393016401417
Non-malignant disorders681344241114019943451436500771502025015033004
Bone marrow failure—SAA186131043637441166141100107201721
Bone marrow failure—other6235401117580507040102661267
Thalassemia1373310061061033485016028916305
Sickle cell disease13195903218840151110503245329
Primary Immune deficiencies14431144510515180128153291706738681
Inherited disorders of Metabolism191703101151004066280402094213
Autoimmune disease—MS000000000000038800388388
Autoimmune disease—SSC000000000000052005252
Autoimmune disease—other22000100041100280202848
Others34221291834014543026016426190
Total patients1191411630216542719541682100183712625124,469018,58924,52043,109
Re/additional transplants311402160352210051539291030760121730864303
Total transplants1222425632227143071561782105289102916127,545019,80627,60647,412
In addition, in Table 2, centers reported information on different types of cellular therapies qualifying as advanced therapy medicinal products (ATMP). These therapies result from substantial manipulations of collected cells, whether manufactured by industry centrally or locally by an academic institution.

Numbers of patients treated with a non HCT cellular therapy in Europe 2021 by indication, donor type and cell source.

Number of patientsDLICARTMSCNK cellsselected/expanded T cells or CIKRegulatory T cells (TREGS)Genetically modified T cellsDendritic cellsExpanded CD34+ cellsGenetically modified CD34+ cellsOtherTotal excluding patients receiving DLI treatments
2021AlloAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAutoAlloAuto
GvHD280171111162918
Graft enhancement258172721523719654
Autoimmune disease417811713
Genetic disease29029
Infection139135155735317421
Malignancy—ALL4233759110152473343
Malignancy—HL/NHL41847151115111854
Malignancy—Other122781332113215173161767343
DLI for graft enhancement/failure848
DLI for residual disease540
DLI for relapse1377
DLI per protocol480
Total3245582466340931517945151101922291729178688292665
Quality control measures included several independent systems: confirmation of validity of data entered by the center, selective comparison of the survey data with MED-A datasets in the EBMT Registry database and crosschecking with National Registries.
Passweg J.R., Baldomero H., Ciceri F., Corbacioglu S., de la Cámara R., Dolstra H., Glass B., Greco R., McLornan D.P., Neven B., de Latour R.P., Perić Z., Ruggeri A., Snowden J.A, & Sureda A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58(6), 647-658.
Full text: Click here
Publication 2023
Cells Cell Therapy Graft Enhancement Grafts Infantile Neuroaxonal Dystrophy Lymphocyte Marrow Patients Pharmacotherapy Relapse Sarcoma Stem Cells Syndrome, Myelodysplastic T-Lymphocyte Tissue Donors Tissues Transplantations, Stem Cell
5
Dextrin-Based Biopharmaceutical Formulation
All reagents used were of the highest degree of purity commercially available, suitable for biopharmaceutical production. Dextrin from Tackidex B 167 (Batch E8747) was kindly provided by Roquette (Lestrem, France), sodium m‐periodate (CAS no. 7790‐28‐5) and diethylene glycol (CAS no. 111‐46‐6) were purchased from BIOCHEM Chemopharma (Cosne sur loire, France). Adipic acid dihydrazide (ADH; CAS no. 1071‐93‐8) was supplied by Merck KGaA (Darmstadt, Germany) and endotoxin free phosphate‐buffered saline (PBS; CAS no. 10049‐21‐5) by BioConcept (Allschwil, Switzerland). BL® was provided by Biosckin, Molecular and Cell Therapies, S.A. (Maia, Portugal).
Machado A., Pereira I., Costa F., Brandão A., Pereira J.E., Maurício A.C., Santos J.D., Amaro I., Falacho R., Coelho R., Cruz N, & Gama M. (2023). Randomized clinical study of injectable dextrin-based hydrogel as a carrier of a synthetic bone substitute. Clinical Oral Investigations, 27(3), 979-994.
Full text: Click here
Publication 2023
167-B adipic dihydrazide Biological Factors Cell Therapy Dextrins diethylene glycol Endotoxins Phosphates Saline Solution sodium metaperiodate

Top products related to «Cell Therapy»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
3
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
4
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
5
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
6
α mem by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, Japan, Australia, France, Italy, Canada, Switzerland, New Zealand, Netherlands, Denmark, Israel, Thailand, Holy See (Vatican City State), Argentina, Ireland
α-MEM is a cell culture medium formulated for the growth and maintenance of mammalian cells. It provides a balanced salt solution, amino acids, vitamins, and other nutrients required for cell proliferation.
7
Facsdiva software by BD
Sourced in United States, Germany, United Kingdom, France, Canada, Belgium, Australia, Italy, Spain, Switzerland, China, Netherlands, Finland, Japan, Jersey, Lao People's Democratic Republic
FACSDiva software is a user-friendly flow cytometry analysis and data management platform. It provides intuitive tools for data acquisition, analysis, and reporting. The software enables researchers to efficiently process and interpret flow cytometry data.
8
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
9
Cd105 by BD
Sourced in United States, China, Germany, Poland, Italy, United Kingdom
CD105 is a laboratory equipment product manufactured by BD. It is a cell surface protein that functions as a co-receptor for the transforming growth factor-beta (TGF-beta) receptor complex. CD105 plays a role in angiogenesis and is expressed on endothelial cells.
10
Human msc analysis kit by BD
Sourced in United States
The Human MSC Analysis Kit is a laboratory equipment product that enables the analysis of human mesenchymal stem cells (MSCs). It provides the core functionality to facilitate the study and characterization of these cell types.

More about "Cell Therapy"

Regenerative Medicine: Cell-based therapies, also known as regenerative medicine, have revolutionized the field of healthcare by offering new treatments for a wide range of degenerative conditions, autoimmune disorders, and cancers.
These innovative therapies utilize living cells, often derived from stem cells or other cell sources, to replace or repair damaged tissues and organs, with the aim of improving patient outcomes.
The dynamic field of cell therapy encompasses a variety of cell types, delivery methods, and optimization strategies, all of which are being continuously explored by researchers to enhance the efficacy and safety of these treatments.
Key components of cell therapy research include the use of fetal bovine serum (FBS), antibiotics such as penicillin/streptomycin and streptomycin, as well as cell culture media like DMEM and α-MEM.
Flow cytometry analysis using FACSDiva software is also a critical tool for characterizing and sorting cell populations, including the identification of key markers like CD105 on human mesenchymal stem cells (MSCs).
Advances in cell therapy research, driven by AI-powered platforms like PubCompare.ai, are revolutionizing the way researchers approach protocol optimization and product selection.
PubCompare.ai's smart comparison tools empower researchers to easily locate the most effective cell therapy protocols from a vast array of literature, preprints, and patents, ultimately streamlining the development of innovative cell-based therapies that have the potential to transform healthcare and improve patient lives.